#Cardiology #ASCVD #ClinicalResearch #CardiovascularRisk #Obesity #EvidenceBasedMedicine #PrecisionMedicine Evolocumab can help attenuate the elevated risk of major adverse cardiovascular events that individuals with obesity and atherosclerotic cardiovascular disease (ASCVD) face, according to a prespecified analysis from the FOURIER trial published in #JACC
GLP-1 receptor agonists work on appetite regulation and metabolic signaling in ways that are largely independent of these hormonal factors, which is why they can be effective even when traditional approaches have stalled
Patients should obtain a detailed prescription letter from their healthcare provider that includes: Patient's full name and date of birth Medication name (generic and brand) Dosage and administration instructions Duration of treatment Physician's contact information and medical license number Statement that medication is for personal use only Some countries require prescriptions to be translated into the local language by a certified translator, notarized, or authenticated by a consulate
All products are available for Collection ONLY at Powerbuilding Gym
Neither outcome is wrongit simply reflects individual biochemistry
Increased LPCs (16:0, 17:0, 18:0), fatty acids (propionic, stearic, octadecanoic, myristic, oleic and linoleic acid), and decreased ketogenic AAs (isoleucine, leucine, threonine phenylalanine, tyrosine), and SM (20:2) at 24 h after admission predicted unfavorable outcomes at 3 months (Table 2) [30]
